S&P 500   3,951.64 (-0.15%)
DOW   33,692.05 (-0.47%)
QQQ   280.50 (-0.02%)
AAPL   141.12 (-0.04%)
MSFT   241.15 (+0.34%)
META   110.82 (+1.24%)
GOOGL   95.49 (+0.32%)
AMZN   92.12 (-0.32%)
TSLA   183.82 (+1.65%)
NVDA   157.51 (+0.72%)
NIO   12.62 (+20.19%)
BABA   87.98 (+10.17%)
AMD   73.44 (+0.07%)
T   18.86 (-0.79%)
MU   53.64 (-2.69%)
CGC   3.40 (-0.58%)
F   13.53 (-1.60%)
GE   84.19 (-1.72%)
DIS   94.04 (-0.69%)
AMC   7.21 (-2.96%)
PYPL   76.25 (-1.79%)
PFE   49.31 (-0.36%)
NFLX   285.93 (+1.77%)
S&P 500   3,951.64 (-0.15%)
DOW   33,692.05 (-0.47%)
QQQ   280.50 (-0.02%)
AAPL   141.12 (-0.04%)
MSFT   241.15 (+0.34%)
META   110.82 (+1.24%)
GOOGL   95.49 (+0.32%)
AMZN   92.12 (-0.32%)
TSLA   183.82 (+1.65%)
NVDA   157.51 (+0.72%)
NIO   12.62 (+20.19%)
BABA   87.98 (+10.17%)
AMD   73.44 (+0.07%)
T   18.86 (-0.79%)
MU   53.64 (-2.69%)
CGC   3.40 (-0.58%)
F   13.53 (-1.60%)
GE   84.19 (-1.72%)
DIS   94.04 (-0.69%)
AMC   7.21 (-2.96%)
PYPL   76.25 (-1.79%)
PFE   49.31 (-0.36%)
NFLX   285.93 (+1.77%)
S&P 500   3,951.64 (-0.15%)
DOW   33,692.05 (-0.47%)
QQQ   280.50 (-0.02%)
AAPL   141.12 (-0.04%)
MSFT   241.15 (+0.34%)
META   110.82 (+1.24%)
GOOGL   95.49 (+0.32%)
AMZN   92.12 (-0.32%)
TSLA   183.82 (+1.65%)
NVDA   157.51 (+0.72%)
NIO   12.62 (+20.19%)
BABA   87.98 (+10.17%)
AMD   73.44 (+0.07%)
T   18.86 (-0.79%)
MU   53.64 (-2.69%)
CGC   3.40 (-0.58%)
F   13.53 (-1.60%)
GE   84.19 (-1.72%)
DIS   94.04 (-0.69%)
AMC   7.21 (-2.96%)
PYPL   76.25 (-1.79%)
PFE   49.31 (-0.36%)
NFLX   285.93 (+1.77%)
S&P 500   3,951.64 (-0.15%)
DOW   33,692.05 (-0.47%)
QQQ   280.50 (-0.02%)
AAPL   141.12 (-0.04%)
MSFT   241.15 (+0.34%)
META   110.82 (+1.24%)
GOOGL   95.49 (+0.32%)
AMZN   92.12 (-0.32%)
TSLA   183.82 (+1.65%)
NVDA   157.51 (+0.72%)
NIO   12.62 (+20.19%)
BABA   87.98 (+10.17%)
AMD   73.44 (+0.07%)
T   18.86 (-0.79%)
MU   53.64 (-2.69%)
CGC   3.40 (-0.58%)
F   13.53 (-1.60%)
GE   84.19 (-1.72%)
DIS   94.04 (-0.69%)
AMC   7.21 (-2.96%)
PYPL   76.25 (-1.79%)
PFE   49.31 (-0.36%)
NFLX   285.93 (+1.77%)
Top-Rated Stocks  
NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$28.78
+1.17 (+4.24%)
(As of 11/30/2022 10:59 AM ET)
Add
Compare
Today's Range
$28.78
▼
$29.65
50-Day Range
$20.37
▼
$29.01
52-Week Range
$12.08
▼
$61.50
Volume
1,578 shs
Average Volume
237,254 shs
Market Capitalization
$854.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.40

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
82.1% Upside
$52.40 Price Target
Short Interest
Bearish
8.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Bicycle Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.82) to ($4.36) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

849th out of 1,043 stocks

Pharmaceutical Preparations Industry

411th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
BCYC stock logo

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

November 27, 2022 | msn.com
Monroe restaurant hosts 5th Annual Holiday Bicycle Drive
November 26, 2022 | marketwatch.com
Bicycle Tyres (Bike Tires) Market Share-Size Estimate 2023 with Top Leading Players & Future Demand, Emerging Trends till 2028
November 25, 2022 | marketwatch.com
Two-Wheel Bicycle Trailer Market 2022 : Production Capacity, Restring Drivers, Size and Landscape Outlook 2028
November 24, 2022 | marketwatch.com
Bicycle Racks Market 2022 Industry Size, Growth, Segments, Revenue, Manufacturers and 2028 Forecast Top Countries Data
November 23, 2022 | marketwatch.com
Bicycle Racks for Cars Market : Revenue, Growth Rate, Market Size, Restraints and Forecast Analysis by 2028
November 23, 2022 | marketwatch.com
Bicycle Gearbox Market Size 2023 Competitive Landscape, Regional Development, Major Manufacturers, Emerging Trends, Growth Opportunities to 2028
November 22, 2022 | marketwatch.com
Bicycle Market 2023 comprehensive report by global industry trends demand growth analysis share revenue and forecast 2028| Newest 126 Pages Report
November 22, 2022 | msn.com
'A lot of work to be done': Bicycle Man struggling to find volunteers for final giveaway
November 10, 2022 | finance.yahoo.com
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 9, 2022 | finance.yahoo.com
Bicycle Therapeutics Third Quarter 2022 Earnings: Misses Expectations
November 8, 2022 | finance.yahoo.com
What You Need To Know About The Bicycle Therapeutics plc (NASDAQ:BCYC) Analyst Downgrade Today
November 8, 2022 | finance.yahoo.com
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 7, 2022 | marketwatch.com
Bicycle Shifters Market Share 2023 Growth Factor, Industry Challenge, Business Overview, Size and Forecast to 2029
November 4, 2022 | marketwatch.com
Electric Assist Bicycle Market 2022 : Report Offers Key Futuristic Top Trends And Competitive Landscape By 2028
November 4, 2022 | marketwatch.com
LED Bicycle Lights Market Research 2022 | Emerging Growth Factors, Key Dynamics, Sales Channel, Trends, Top Manufacturers and Size Forecast to 2028
November 3, 2022 | benzinga.com
Insights on the Bicycle Global Market to 2027 - Electric Segment Shows Promising Growth
November 3, 2022 | marketwatch.com
Folding Electric Bicycle Market Size, Share, Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2028
November 3, 2022 | benzinga.com
Recap: Bicycle Therapeutics Q3 Earnings
November 3, 2022 | finance.yahoo.com
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 2, 2022 | marketwatch.com
Bicycle Rear Derailleurs Market Size with SWOT Analysis is Likely to Accelerate Industry Growth in Consumer Goods
November 1, 2022 | marketwatch.com
Bicycle Stems Market Report : Global Size, Share, Growth and Industry Trends 2022 To 2028 | 120 Report Pages
October 29, 2022 | marketwatch.com
Bicycle Rear Derailleurs Market Size with SWOT Analysis & Unlimited Opportunities for New Companies from 2022 To 2028
October 28, 2022 | msn.com
‘A transformative project’: Utah’s Bicycle Collective is getting a new home
October 26, 2022 | msn.com
Bicycle Collective to build new Salt Lake City ‘hub’ off 9 Line Trail
October 10, 2022 | finance.yahoo.com
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings
11/03/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCYC
CUSIP
N/A
CIK
1761612
Web
www.bicycletherapeutics.com
Phone
441223261503
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.40
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+82.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,820,000.00
Net Margins
-669.65%
Pretax Margin
-681.96%
Return on Equity
-31.56%
Return on Assets
-22.37%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
9.18
Quick Ratio
9.18

Sales & Book Value

Annual Sales
$11.70 million
Price / Sales
73.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.75 per share
Price / Book
2.95

Miscellaneous

Outstanding Shares
29,690,000
Free Float
27,017,000
Market Cap
$854.48 million
Optionable
Not Optionable
Beta
0.76

Key Executives

  • Dr. Kevin Lee M.B.A. (Age 53)
    Ph.D., CEO & Exec. Director
    Comp: $1.4M
  • Mr. Lee H. Kalowski M.B.A. (Age 41)
    MBA, Pres & CFO
    Comp: $832.36k
  • Sir Gregory Paul Winter CBE (Age 71)
    FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
    Comp: $40k
  • Dr. Michael Skynner B.sc. Ph.d. (Age 52)
    Ph.D., Chief Technology Officer
    Comp: $925.3k
  • Dr. Christian Heinis
    Scientific Founder
  • Mr. Alistair Milnes
    Chief Operating Officer
  • Dr. Nicholas Keen Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. David E. Borah CFA
    VP of Capital Markets & Investor Relations
  • Mr. Zafar Qadir
    Gen. Counsel
  • Dr. Gillian Langford
    Head of Clinical and Project Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.

What is Bicycle Therapeutics' stock price forecast for 2023?

12 brokerages have issued 12 month price objectives for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's share price to reach $52.40 in the next year. This suggests a possible upside of 89.8% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2022?

Bicycle Therapeutics' stock was trading at $60.87 at the beginning of the year. Since then, BCYC shares have decreased by 54.6% and is now trading at $27.61.
View the best growth stocks for 2022 here.

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,550,000 shares, a drop of 8.6% from the October 31st total of 2,790,000 shares. Based on an average daily volume of 218,700 shares, the short-interest ratio is currently 11.7 days.
View Bicycle Therapeutics' Short Interest.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCYC earnings forecast.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.02. The company earned $4.33 million during the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 31.56% and a negative net margin of 669.65%.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Logos Global Management LP (6.74%), Samlyn Capital LLC (4.36%), Point72 Asset Management L.P. (4.23%), Tybourne Capital Management HK Ltd. (3.51%), First Light Asset Management LLC (2.37%) and Price T Rowe Associates Inc. MD (1.41%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $27.61.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $819.71 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

The company employs 119 workers across the globe.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.

This page (NASDAQ:BCYC) was last updated on 11/30/2022 by MarketBeat.com Staff